Download PDF
Market: Hong Kong
Stock Code: 2137.HK
ISIN: KYG1645A1094
Industry : Biotechnology

Brii Biosciences Limited (“Brii Bio”, or the “Company”, stock code: 2137.HK) is a biotechnology company based in China and the United States committed to advancing therapies for significant infectious diseases, such as hepatitis B, COVID-19, human immunodeficiency virus (HIV) infection, multi-drug resistant (MDR) or extensive drug resistant (XDR) gram-negative infections, and other illnesses, such as the central nervous system (CNS) diseases, which have significant public health burdens in China and worldwide.

Share Graph
Share Data
25/11/2022
Currency HKD
Previous Close 7.78
Change (%) -4.66
Volume 8,660,000
Number of Shares(mil) 726.76
Share Market Cap (mil) 5,654.16
Pipeline
Indication Program Preclinical IND Phase 1 Phase 2 Phase 3 NDA/BLA Regulatory Authority Brii Rights Licensing Partners/Internally Discovered
Infectious Disease Programs
Hepatitis B
BRII-179 (VBI-2601)/BRII-835 (VIR-2218) Combination
NMPA Greater China
BRII-179 (VBI-2601)/PEG-IFN-α Combination
NMPA Greater China
BRII-877 (VIR-3434)(1)
NMPA Greater China
COVID-19
Amubarvimab/romlusevimab Combination(2)
(previously BRII-196/BRII-198)
China BLA approved and commercial launched
NMPA/FDA Global
Under US EUA review
HIV infection
BRII-778
FDA Global Internally discovered
BRII-732(3)
FDA Global Internally discovered
MDR/XDR
gram-negative
infections
BRII-636(4)(OMNIvance®)
FDA Greater China
BRII-672(4)(ORAvanceTM)
FDA Greater China
BRII-693(4)(QPX-9003)
FDA Greater China
Nontuberculosis mycobacteria
BRII-658(4)(Epetraborole)
FDA Greater China
Central Nervous System Disease Programs
PPD
BRII-296
FDA Global Internally discovered
PPD prevention
BRII-296
FDA Global Internally discovered
Anxiety &
Depressive
disorder
BRII-297
FDA Global Internally discovered
Source: Company information

Notes:
1. The Phase 2 clinical trials have been conducted by VIR.
2. The filing of EUA application with FDA for combination amubarvimab/romlusevimab has been completed in December 2021.
3. Phase 1 study of BRII-732 is currently on clinical hold as part of FDA’s decision to temporarily hold islatravir-based clinical studies.
4. To this date, the development and clinical trials have been conducted by Qpex and AN2, respectively.
Board of Directors
Audit and
Risk Committee
Nomination
Committee
Remuneration
Committee
Strategic
Committee
Executive
Directors
Non-executive
Directors
Independent
Non-executive
Directors
Dr. Zhi HONG
Dr. Ankang LI
Mr. Robert Taylor NELSEN
Dr. Martin J MURPHY JR
 
Ms. Grace Hui TANG
 
Mr. Yiu Wa Alec TSUI
 
Mr. Gregg Huber ALTON
 
Dr. Taiyin YANG
= Chairperson    = Member
Corporate Executive Team

Susannah Cantrell, Ph.D.

Chief Business Officer

Eleanor (Ellee) de Groot, Ph.D.

Chief Technology Officer

Zhi Hong, Ph.D.

Zhi Hong, Ph.D.

Executive Director,
Chairman of the Board and Chief Executive Officer

Rico Liang

Ankang Li, Ph.D., J.D., CFA

Chief Strategy and Financial Officer,
Chief Executive Officer of TSB Therapeutics

Rico Liang

Rico Liang

General Manager,
Greater China

David Margolis, M.D., MPH

Head of Infectious Diseases Therapy Area

Karen D. Neuendorff

Chief People Officer and Head of Human Resources

Aleksandar Skuban, M.D.

Head of CNS Diseases Therapy Area

Coy Stout

Head of Patient Advocacy

Lianhong Xu, Ph.D.

Lianhong Xu, Ph.D.

Head of Discovery

Li Yan, M.D., Ph.D.

Li Yan, M.D., Ph.D.

Chief Medical Officer

Qing Zhu, Ph.D.

Qing Zhu, Ph.D.

Head of China R&D

Financial Highlights
BRII-B (RMB'000) 2019 2020 2021
Operating Results      
Other income 20,339 84,625 99,032
Other gains and losses 8,440 (21,993) 45,062
Research and development expenses (83,785) (875,795) (494,615)
Administrative expenses (63,334) (103,396) (208,404)
Fair value loss on financial liabilities at FVTPL (401,575) (350,372) (3,598,847)
Finance costs (1,113) (1,668) (1,175)
Listing expenses - (14,911) (32,137)
Loss for the year (521,028) (1,283,510) (4,191,084)
Financial Position      
Total assets 1,039,424 1,267,944 3,611,699
Total liabilities 1,652,185 3,010,646 300,443
Total equity (deficits) (612,761) (1,742,702) 3,311,256
Selected Items from Consolidated Cash Flow Statement      
Net cash used in operating activities (67,276) (403,716) (879,457)
Net cash used in investing activities (92,781) (43,650) (475,756)
Net cash from financing activities 518,347 657,001 3,230,134
Net increase in cash and cash equivalents 358,290 209,635 1,874,921
Cash and cash equivalents at end of the year 880,359 1,034,965 2,855,093
Key indicators      
Loss per share - Basic and diluted (RMB) (2.92) (6.22) (9.48)
Current Ratio 14.3 1.9 12.15